PlumX Metrics
Embed PlumX Metrics

Donor cell-derived leukemia after cord blood transplantation and a review of the literature: Differences between cord blood and BM as the transplant source

Bone Marrow Transplantation, ISSN: 0268-3369, Vol: 49, Issue: 1, Page: 102-109
2014
  • 29
    Citations
  • 0
    Usage
  • 30
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Greffe de moelle osseuse : quand les cellules du donneur deviennent leucémiques

Phénomène très rare, transfusées à un patient leucémique en rémission, les cellules souches d’un donneur en bonne santé peuvent à leur tour devenir leucémiques.

Review Description

Donor cell-derived leukemia (DCL) is a rare complication of SCT. Here, we present a case of DCL following cord blood transplantation (CBT) and review the clinical features of previously reported DCL. To our knowledge, this is the first report comparing clinical characteristics of DCL from the standpoint of the transplant source, with umbilical cord blood and BM. AML and myelodysplastic syndrome (MDS) were recognized more frequently in DCL after CBT, whereas the incidence of AML and ALL was similar after BMT. The median duration between the occurrence of DCL following CBT and BMT was 14.5 and 36 months, respectively. DCL occurred in a significantly shorter period after CBT than after BMT. Abnormal karyotypes involving chromosome 7 were observed in 52.4% of CBT recipients and 17.3% of BMT recipients; this was a statistically significant difference. Particularly, the frequency of monosomy 7 was significantly higher in DCL after CBT than after BMT. The types of abnormal karyotypes in DCL following BMT were similar to those characteristically observed in adult de novo AML and MDS. DCL patients generally have a poor prognosis in both groups. SCT is the best treatment for curing DCL. DCL appears to have different clinical features according to the transplant source.

Bibliographic Details

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know